Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13

被引:14
|
作者
Tersteeg, Claudia [1 ]
Fijnheer, Rob [2 ]
Pasterkamp, Gerard [2 ]
de Groot, Philip G. [2 ]
Vanhoorelbeke, Karen [1 ]
de Maat, Steven [2 ]
Maas, Coen [2 ]
机构
[1] Katholieke Univ Leuven, IRF Life Sci, Lab Thrombosis Res, Campus Kulak Kortrijk, Kortrijk, Belgium
[2] UMC Utrecht, Lab Clin Chem & Hematol, Heidelberglaan 100,G-03-550, NL-3584 CX Utrecht, Netherlands
来源
SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2016年 / 42卷 / 01期
关键词
ADAMTS13; plasmin; VWF; thrombotic thrombocytopenic purpura; thrombotic microangiopathy; THROMBOTIC THROMBOCYTOPENIC PURPURA; NEUTROPHIL EXTRACELLULAR TRAPS; UROKINASE RECEPTOR EXPRESSION; TISSUE-PLASMINOGEN-ACTIVATOR; FACTOR-CLEAVING PROTEASE; DNA TRAPS; VONWILLEBRAND-FACTOR; EMERGENCY BYPASS; DISEASE-ACTIVITY; FACTOR MULTIMERS;
D O I
10.1055/s-0035-1564838
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Von Willebrand factor (VWF) is one of the most important proteins of the hemostatic system. Its multimeric state is essential for its natural function to guide platelets to sites of injury. ADAMTS13 is the key protease that regulates the multimeric state of VWF. Without ADAMTS13, VWF multimers can grow to pathologically large sizes. This is a risk factor for the life-threatening condition thrombotic thrombocytopenic purpura (TTP). In this condition, VWF-rich thrombi occlude the microvasculature of various tissues. Intriguingly, a complete ADAMTS13 deficiency does not cause continuous TTP, either in patients or genetically targeted mice. Instead, TTP occurs in episodes of disease, separated by extended periods of remission. This indicates that regulating factors beyond ADAMTS13 are likely involved in this pathologic cascade of events. This raises the question of what really happens when ADAMTS13 is (temporarily) unavailable. In this review, we explore the possible role of complementary mechanisms that are capable of modifying the thrombogenic potential of VWF.
引用
收藏
页码:9 / 17
页数:9
相关论文
共 50 条
  • [1] Binding of ADAMTS13 to von Willebrand factor
    Majerus, EM
    Anderson, PJ
    Sadler, JE
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (23) : 21773 - 21778
  • [2] ADAMTS13 and von Willebrand factor interactions
    Zander, Catherine B.
    Cao, Wenjing
    Zheng, X. Long
    CURRENT OPINION IN HEMATOLOGY, 2015, 22 (05) : 452 - 459
  • [3] Inflammation, von Willebrand factor, and ADAMTS13
    Chen, Junmei
    Chung, Dominic W.
    BLOOD, 2018, 132 (02) : 141 - 147
  • [4] von Willebrand factor, ADAMTS13, and thrombotic microangiopathy
    Sadler, J. E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 251 - 251
  • [5] Allosteric activation of ADAMTS13 by von Willebrand factor
    Muia, Joshua
    Zhu, Jian
    Gupta, Garima
    Haberichter, Sandra L.
    Friedman, Kenneth D.
    Feys, Hendrik B.
    Deforche, Louis
    Vanhoorelbeke, Karen
    Westfield, Lisa A.
    Rothe, Robyn
    Tolia, Niraj Harish
    Heuser, John E.
    Sadler, J. Evan
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (52) : 18584 - 18589
  • [6] ASSOCIATION OF ADAMTS13 AND VON WILLEBRAND FACTOR TO PREECLAMPSIA
    Lokki, A. Inkeri
    Triebwasser, Michael
    Daly, Emma
    Daly, Mark
    Lassila, Riitta
    Atkinson, John P.
    Meri, Seppo
    Laivuori, Hannele
    MOLECULAR IMMUNOLOGY, 2019, 114 : 465 - 466
  • [7] Unproductive binding of ADAMTS13 to von willebrand factor
    Feys, H. B.
    Anderson, P. J.
    Vanhoorelbeke, K.
    Sadler, J. E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 9 - 9
  • [8] ADAMTS13 and von Willebrand Factor in Thrombotic Thrombocytopenic Purpura
    Zheng, X. Long
    ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 211 - 225
  • [9] Von Willebrand factor, ADAMTS13 and mortality in dialysis patients
    Ocak, Gurbey
    Roest, Mark
    Verhaar, Marianne C.
    Rookmaaker, Maarten B.
    Blankestijn, Peter J.
    Bos, Willem Jan W.
    Fijnheer, Rob
    Pequeriaux, Nathalie C.
    Dekker, Friedo W.
    BMC NEPHROLOGY, 2021, 22 (01)
  • [10] VON WILLEBRAND FACTOR, ADAMTS13 AND MORTALITY IN DIALYSIS PATIENTS
    Ocak, G.
    Roest, M.
    Verhaar, M. C.
    Rookmaaker, M. B.
    Blankestijn, P. J.
    Fijnheer, R.
    Pequeriaux, N. C. V.
    Dekker, F. W.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34